Dr Neal Shore, Assoc. Prof. Neeraj Agarwal and Prof. Steven Joniau provide their thoughts and views on treatments for newly diagnosed mHSPC (Metastatic Hormone Sensitive Prostate Cancer) patients following recent cutting-edge trials.
An update on recent cutting-edge trials: Treatments now available for newly diagnosed mHSPC patients
Dr Neal Shore, Assoc. Prof. Neeraj Agarwal, and Prof. Steven Joniau provide their thoughts on treatments for newly diagnosed mHSPC (Metastatic Hormone Sensitive Prostate Cancer) patients following recent cutting-edge trials. These slides and video cover recent trials including CHAARTED, STAMPEDE, and LATITUDE. We are given an update on combination trials and how these might improve patient care while moving away from monotherapy.
Emerging treatment options
Dr Shore gives a comprehensive introduction, outlining the need for improved treatment options in prostate cancer. Data from the CHAARTED trial is discussed, in which androgen ablation therapy is used with or without docetaxel chemotherapy for treatment of patients with metastatic prostate cancer. Drug efficacy of systemic therapy in advancing or metastatic prostate cancer is evaluated in the STAMPEDE trial. The LATITUDE trial examines androgen deprivation therapy with abiraterone acetate plus prednisone in newly diagnosed high-risk metastatic hormone-naïve prostate cancer patients. Dr Shore discusses survival benefits and hazard ratios (HRs) and addresses clinical questions regarding treatment protocols, how to monitor subpopulations of patients needing tailored care, and what decisions need to be made following castration-resistance.
The North American perspective in treating prostate cancer
Prof. Agarwal gives us the North American perspective and addresses what treatment options to offer patients in a backdrop of limited data comparing docetaxel chemotherapy to abiraterone acetate. The pros and cons of treatment options are covered as well as considerations in patient and practitioner choice. Addressed are future directions including the role of biomarkers in treatment choice.
The European perspective in treating prostate cancer
Finally, Prof. Joniau provides insight into the European perspective. He covers the European Association of Urology treatment guidelines, and treatment selection factors to be considered when deciding on whether to combine ADT with abiraterone or docetaxel. Highlighted are patients with oligo-metastatic disease, and how ongoing studies aim to address current gaps in knowledge when treating this patient group. This video with accompanying slides provides practical guidance to oncologists and urologists, and we hope you find it a useful resource for improving your clinical practice.